3. Kim SY, Cheong HK, An SS. Human prion diseases. J Korean Med Assoc 2008;51:1125-1138 (Korean).
4. Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-188. PMID:
371520
6. Duffy P, Wolf J, Collins G, DeVoe AG, Streeten B, Cowen D. Letter: possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974;290:692-693.
7. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003;66:255-265. PMID:
14522863
9. Rappaport EB. Iatrogenic Creutzfeldt-Jakob disease. Neurology 1987;37:1520-1522. PMID:
3306455
10. Food and Drug Administration (FDA). FDA safety alert: possibly contaminated dura mater transplant material. Rockville: US Department of Health and Human Services, Public Health Service; 1987. p 1-15.
12. Triendl R. CJD link prompts ban on brain tissue use. Nature 1997;387:5.
13. Tanaka S, Fukushima M. Size of Creutzfeldt-Jakob disease epidemic associated with cadaveric dura transplantation. Neuroepidemiology 2010;34:232-237. PMID:
20299804
14. Lui KJ, Darrow WW, Rutherford GW 3rd. A model-based estimate of the mean incubation period for AIDS in homosexual men. Science 1988;240:1333-1335. PMID:
3163848
15. Kaplan ME, Schonberg SK. HIV in adolescents. Clin Perinatol 1994;21:75-84. PMID:
8013187
16. Cox DR, Oakes D. Analysis of survival data. London: Chapman & Hall; 1984. p 32-45.
17. Gross AJ, Clark VA. Survival distributions: reliability applications in the biomedical sciences. New York: John Wiley; 1975. p 112-113.
18. Hamada C, Sadaike T, Fukushima M. Projection of Creutzfeldt-Jakob disease frequency based on cadaveric dura transplantation in Japan. Neuroepidemiology 2003;22:57-64. PMID:
12566955
19. Nagatsu T. Molecular mechanisms of neurotransmission. Rinsho Shinkeigaku 2000;40:1185-1188 (Japanese). PMID:
11464453
21. Hoshi K, Yoshino H, Urata J, Nakamura Y, Yanagawa H, Sato T. Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts in Japan. Neurology 2000;55:718-721. PMID:
10980745
22. Centers for Disease Control and Prevention. Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts--Japan, 1978-2008. MMWR Morb Mortal Wkly Rep 2008;57:1152-1154. PMID:
18946463
23. Brooke FJ, Boyd A, Klug GM, Masters CL, Collins SJ. Lyodura use and the risk of iatrogenic Creutzfeldt-Jakob disease in Australia. Med J Aust 2004;180:177-181. PMID:
14960140
24. Brandel JP, Peckeu L, Haïk S. The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide. Transfus Clin Biol 2013;20:395-397. PMID:
23587616
25. Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006;67:389-393. PMID:
16855204
26. Hamaguchi T, Sakai K, Noguchi-Shinohara M, Nozaki I, Takumi I, Sanjo N, et al. Insight into the frequent occurrence of dura mater graftassociated Creutzfeldt-Jakob disease in Japan. J Neurol Neurosurg Psychiatry 2013;84:1171-1175. PMID:
23595947
27. Tateishi J. Creutzfeldt-Jakob disease transmitted through cadaveric dura transplantation. J Clin Exp Med 1997;181:992-993 (Japanese).
28. Nakamura Y, Aso E, Yanagawa H. Relative risk of Creutzfeldt-Jakob disease with cadaveric dura transplantation in Japan. Neurology 1999;53:218-220. PMID:
10408565